top

For decades, psychedelics have been shrouded in mystery and taboo, associated with countercultural movements and recreational drug use. But today, a growing body of scientific research is unveiling the remarkable therapeutic potential of these substances.

From treating addiction and depression to easing end-of-life anxiety and helping people confront deep-seated emotional traumas, psychedelics are being explored as a new frontier in medicine. This multi-part film series takes an in-depth look at the history, science, and cultural significance of psychedelic medicine, and follows the stories of individuals whose lives have been transformed by these substances.

Each episode of this multi-episode documentary film series focuses on the potential therapeutic use of a wide variety of compounds including DMT, Ketamine, LSD, MDMA, Psilocybin, and Ibogaine. We are examining the merging worlds of the biopharmaceutical companies working on the cutting edge of psychedelic medicines with the archaic techniques of the shaman working directly with the plants themselves.

Our mission is to present our audience with a broad view of the therapeutic potential of psychedelics while peering around the corner into the future of psychedelic medicines.

Beyond the Veil

Exploring the New Frontier of Psychedelic Medicine

This film series features renowned experts in the field of psychedelics who have generously agreed to share their insights and experiences with us. These individuals have dedicated their lives and careers to exploring the world of psychedelics and have made significant contributions to the field. As we continue to develop this documentary series, more experts will be joining us to provide their perspective and knowledge. Stay tuned for updates on our impressive lineup of contributors.

Featuring Interviews With:

Rick Doblin, Ph.D.

Founder and Executive Director - MAPS.org

Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He first founded MAPS in 1986 and still continues today. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people.

Dr. Rick Strassman

Clinical Associate Professor of Psychiatry at the University of New Mexico School of Medicine

Dr. Strassman’s “DMT: The Spirit Molecule,” an account of his DMT and psilocybin studies, has sold more than a quarter-million copies. He also is the author of “DMT and the Soul of Prophecy,” “Joseph Levy Escapes Death,” and a co-author of “Inner Paths to Outer Space.” His new book, "The Psychedelic Handbook : A Step-By-Step Guide to the Transformative Power of Psilocybin, LSD, DMT, Peyote, and More" is now available.

Dr. Dennis McKenna

Principal Founder & President at McKenna Academy of Natural Philosophy

Dennis McKenna, co-founder of the Heffter Institute, is an ethnopharmacologist, research pharmacognosist, lecturer, and author. Dennis has pursued interdisciplinary research in the study of Amazonian ethnopharmacology and plant hallucinogens for over 30 years. Dennis McKenna’s professional and personal interests are focused on the interdisciplinary study of ethnopharmacology and natural hallucinogens.

Wade Davis

Ethnobotanist, Author

Wade Davis is a cultural anthropologist, ethnobotanist, author, and photographer. Wade Davis is also an Explorer in Residence at the National Geographic Society. He is the author of 15 books, including the bestseller, Serpent and the Rainbow. Wade spent more than 3 years in the Amazon and Andes as a plant explorer, living among 15 indigenous groups in 8 nations while making some 6,000 botanical collections.

Jesse Gould

Founder / President of The Heroic Hearts Project

Heroic Hearts Project offers a proprietary program to veterans who are interested in pursuing psychedelic treatment options. After being deployed as an Army Ranger in Afghanistan three times, he founded the Heroic Hearts Project in 2017 to spearhead the acceptance and use of ayahuasca therapy as a means of addressing the current mental health crisis among veterans.

Dr. Jackie von Salm

CoFounder of Psilera

Jackie von Salm and Chris Witowski are using psychoactive natural products as building blocks. Together with their team at Psilera, they are designing the next generation of neurological therapeutics. Psilera is taking centuries of knowledge and applying 21st-century technology and innovation to establish a new era in mindful medicine.

Dr. Chris Witowski

CoFounder of Psilera

Chris Witowski and Jackie von Salm are using psychoactive natural products as building blocks. Together with their team at Psilera, they are designing the next generation of neurological therapeutics. Psilera is taking centuries of knowledge and applying 21st-century technology and innovation to establish a new era in mindful medicine.

Ethan Russo, MD

Neurologist, Psychopharmacology Researcher, and Author.

Ethan Russo's research interests have included correlations of historical uses of cannabis to modern pharmacological mechanisms. He is the author of Handbook of Psychotropic Herbs, co-editor of Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential, and author of The Last Sorcerer: Echoes of the Rainforest.

Josh Kaplan

Assistant Professor in the Behavioral Neuroscience - Western Washington University

Dr. Kaplan's expertise is in neurophysiology, neuropharmacology, and animal behavior techniques, which his lab uses to study the therapeutic benefits and developmental consequences of cannabis in pre-clinical rodent models. His research seeks to optimize cannabinoid and terpene compositions to maximize benefits and minimize adverse consequences.

Don Lattin

Award-winning journalist and author of six books.

Don Lattin's most recent work, CHANGING OUR MINDS - Psychedelic Sacraments and the New Psychotherapy chronicles a quiet revolution underway in our understanding of how psychedelic drugs work and how they can be used to treat depression, addiction, and other diseases. The stories behind this cutting-edge medical research and religious exploration reveal the human side of a psychedelic renaissance.

Daniel Karlin, MD, MA

Chief Medical Officer at MindMed

Dan is Board Certified in Psychiatry, Addiction Medicine, and Clinical Informatics. He is an Assistant Professor of Psychiatry at Tufts University School of Medicine. He graduated with degrees in Neuroscience and Behavior (BA), and Clinical Informatics (MA), Columbia University; Medicine (MD), University of Colorado School of Medicine.

Prof. David Nutt

Chief Research Officer at Awakn Life Sciences

Prof. David Nutt is the Founding Chair of the charity Drug Science and PAREA the European association for access to research with psychedelics. Previously, he was President f the European Brain Council and of the European College of Neuropsychopharmacology. The Times Eureka science magazine voted him one of the 100 most important figures in British Science.

Prof. Celia Morgan

Head of Ketamine Assisted Psychotherapy for Addiction at Awakn Life Sciences

Celia is a Professor of Psychopharmacology at the University of Exeter in the United Kingdom. Prof. Morgan completed her undergraduate degree and Ph.D at University College London (UCL) and completed a scholarship program at Yale University. Prof. Morgan is the academic lead for both Exeter Translational Addiction Partnership (ETAP) and Ketamine for Reduction of Alcoholic Relapse (KARE).

Dr. Ben Sessa

Co-Founder and head of psychedelic Medicine - Akakn Life Sciences

Dr Sessa’s joint interests in psychotherapy, pharmacology, and trauma have led him towards researching the subject of drug-assisted psychotherapy using psychedelic adjuncts. In the last 15 years, he has been part of scientific and clinical studies administering LSD, psilocybin, ketamine, MDMA, and DMT to patients and volunteers.

Ian McCall

Founder of the McCall Method

Ian McCall is a retired Mixed Martial Arts World Champion, Psychedelic Research Advocate, Decriminalize California Event Director, Psilocybin Advocate, Performance Coach & Mentor.

Ian is the world’s first psychedelic integration coach for high-level sports.

Robert Barrow

Chief Executive Officer and Board Director

- MindMed

Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas.

After joining MindMed as Chief Development Officer in January 2021, he was named CEO of MindMed in June 2021.

...and many others!

These are the types of moments that will be remembered and reflected upon for years to come. Together, we have the opportunity to help change history for psychedelics and mental health worldwide. I invite you to join us and be a part of this important and historic change in the field of psychedelic medicine.

If you are interested in supporting this film project through funding, the best way to do so at this time is to reach out to me directly.